Should We Retain Half-Dose ARNIs in HFrEF? Lessons Learned from Reverse Remodeling using CORE-HF Real-World Data

Irnizarifka Irnizarifka; Irsyad Ristiansah; Habibie Arifianto; Trisulo Wasyanto

International Cardiovascular Research Journal

The Official Annually Journal of Cardiovascular Research Center, Shiraz University of Medical Sciences

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards & Committees Indexing and Listing Sources Journal Metrics Publication Ethics and Publication Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

Should We Retain Half-Dose ARNIs in HFrEF? Lessons Learned from Reverse Remodeling using CORE-HF Real-World Data

Author(s):

Irnizarifka Irnizarifka

^{1, 2,*},

Irsyad Ristiansah

²,

Habibie Arifianto

^{1, 2},

Trisulo Wasyanto¹

1Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Sebelas Maret, Surakarta, Indonesia

2HF Clinic Team of Universitas Sebelas Maret Hospital, Sukoharjo, Indonesia

International Cardiovascular Research Journal:Vol. 16, issue 3; e129234

Published online:Sep 30, 2022

Article type:Research Article

Received:Jun 20, 2022

Accepted:Oct 01, 2022

How to Cite:Irnizarifka IrnizarifkaIrsyad RistiansahHabibie ArifiantoTrisulo WasyantoShould We Retain Half-Dose ARNIs in HFrEF? Lessons Learned from Reverse Remodeling using CORE-HF Real-World Data.Int Cardiovasc Res J.16(3):e129234.

Abstract

Background: Heart failure (HF) is a progressive health problem with high mortality and morbidity rates in both developed and developing countries. Patients with HF who develop reverse remodeling during treatment have better outcomes and lower mortality. Real-world data on the reverse remodeling effects of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor-neprilysin inhibitors (ARNIs) in Indonesians are yet to be available.

Objectives: This study aimed to compare the reverse cardiac remodeling of patients with heart failure with reduced ejection fraction (HFrEF) treated for six months with an ARNI or ACEI based on the CORE-HF registry.

Methods: We conducted a non-experimental, sub-analysis study of the CORE-HF database at the Heart Failure Clinic of Universitas Sebelas Maret Hospital from 2018 to 2021. One group had been treated with ARNIs, while the other was administered with the optimal tolerated ACEI. A six-month follow-up was carried out to determine left ventricle reverse remodeling (LVRR) and functional class alteration as endpoints.

Results: While 89.2% of those in the ACEI group could tolerate the maximum dose, only one person in the ARNI group received the maximum dose, with the majority receiving half the maximum dose (100 mg BID). After six months, LVRR occurred at a similar rate in both groups (26.31% for ARNI and 26.15% for ACEI; P = 0.989). However, the New York Heart Association functional class improved more in the ARNI group (mean 0.95 ± 0.7 vs. 0.62 ± 0.86; P = 0.128).

Conclusions: Despite similar LVRR and functional capacity improvements, a slightly better echocardiography improvement was observed in the ACEI arm. We postulate that full intervention of the renin-angiotensin-aldosterone system should still be the main goal, together with other guideline-directed medical therapies for HF. Hence, cost-effective full-dose of ACEi should be chosen for low- to middle-income countries whose ARNI was not easily available yet due to several issues.

Keywords

Heart failure

Reduced Ejection Fraction

LCZ 696

Ventricular Remodeling

Fulltext

The full-text is available in pdf.

References

1.
The references are available in pdf.

comments